abiraterone acetate / Generic mfg. - LARVOL DELTA

Stabilization of Abiraterone in Human Plasma Using the Esterase Inhibitor Bis(4-nitrophenyl) Phosphate: A Short Communication. (PubMed, Ther Drug Monit) - "We demonstrated that the esterase inhibitor BNPP effectively stabilizes abiraterone in fresh human K2EDTA plasma. BNPP had no significant effect on the accuracy, precision, selectivity, or specificity of LC-MS/MS for abiraterone detection. The addition of BNPP to clinical abiraterone samples may be helpful in implementing abiraterone TDM in daily clinical practice."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes. (PubMed, Onco Targets Ther) - "A new prognostic model described by our group combines molecular characteristics (ptDNA levels), metabolic features from PET-scans (metabolic tumor volume), clinical parameters (visceral metastases), and lab tests (lactate-dehydrogenase levels) in abiraterone or enzalutamide-treated patients...The prognostic score has confirmed to be a good prognostic tool also in a more advanced cohort of patients treated with taxanes. This tool may represent a valid method to refine prognostication and treatment selection in a cohort of patients where biomarkers are scarce."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Early Access Program in oncology: Retrospective study at a Portuguese hospital (ECOP 2024) - "During the study period were submitted 163 EAP requests for abiraterone, amivantamab, bevacizumab, durvalumab, encorafenib, enfortumab, everolimus, erdafitinib, lenvatinib, lurbinectedin, niraparib, nivolumab, olaparib, pembrolizumab, pertuzumab, ramucirumab, sacituzumab govitecan, selpercatinib, trifluridine/tipiracil, trametinib+dabrafenib, trastuzumab-deruxtecan and tucatinib. Conclusion Most cases correspond to metastatic disease, EAPs facilitate timely access to innovative therapies for patients with high unmet medical needs. The majority of situations were financed, which confirms the importance of EAPs in an era where oncology is constantly innovating."

Retrospective data • Gastrointestinal Disorder • Oncology

Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer. (PubMed, Prostate Cancer) - "The levels of androgens during treatment with abiraterone acetate with prednisone (AAP) are lower than those achieved by androgen-deprivation therapy only, potentially resulting in a high risk of skeletal muscle loss. SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Sarcopenia • Solid Tumor

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - P=N/A | N=2731 | Completed | Sponsor: Pfizer | Trial completion date: Oct 2024 ➔ Feb 2025 | Trial primary completion date: Oct 2024 ➔ Feb 2025

Real-world evidence • Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation. (PubMed, Target Oncol) - P3 | "Key clinical and safety data in BRCAm subgroup populations are discussed, predominantly based on findings from PROfound and PROpel, as well as investigator-initiated studies, to help inform treatment decision-making in this patient population. We also discuss the importance of genetic testing to identify patients who may optimally benefit from treatment with olaparib, either as a monotherapy or in combination with abiraterone."

Journal • Monotherapy • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HRD

Before and After (ATS 2025) - "The patient was treated with abiraterone, prednisone, and leuprolide injections. This case reiterates that the pulmonary-only metastatic presentations of prostate cancer can be treated without surgery and with androgen deprivation therapy only, yielding a good clinical response. Ongoing follow-up and a multidisciplinary approach are essential for optimizing outcomes in similar patients."

Genito-urinary Cancer • Oncology • Prostate Cancer • Pulmonary Disease • Respiratory Diseases • Solid Tumor

5041: Using real-world data to provide insights into treatment that has a lower chance of causing heart attack and stroke in prostate cancer patients (City of Hope) - "Dr. Bryce led a group of scientists who analyzed the data of more than 68 million seniors who are U.S. Medicare and Medicaid beneficiaries. They included mCRPC patients who were 65 or older and have never had chemotherapy. Patients were then stratified into subgroups based on cardiovascular disease history. People treated with abiraterone acetate had a statistically significant higher risk of experiencing cardiovascular events like heart attacks, strokes, coronary revascularization to restore blood flow, heart failure, irregular heart rhythm and blood clots compared to mCRPC patients treated with enzalutamide. Additionally, the researchers found that the risk of death was higher with abiraterone acetate than with enzalutamide regardless of cardiovascular disease history."

Adverse events • Real-world • Retrospective data • Castration-Resistant Prostate Cancer

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Weill Medical College of Cornell University | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CTCs

Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE. (ASCO 2025) - P2/3 | "Funded by Prostate Cancer Foundation Clinical Trial Registration Number: NCT00268476 Background: The STAMPEDE trials showed that adding abiraterone acetate + prednisolone (AAP) ± enzalutamide (ENZ) to standard of care androgen deprivation therapy (SOC) improves metastasis-free survival (MFS) in high-risk non-metastatic (M0) prostate cancer (PCa) patients (pts). For the first time, we demonstrate that a validated MMAI algorithm can identify high-risk non-metastatic PCa pts most likely to benefit from the addition of ARPI. Notably we identify a positive biomarker-treatment interaction in the highest MMAI score quartile, which in cases of clinical equipoise could inform clinical decision-making. We highlight MMAI's potential to optimize treatment decisions & spare biomarker-neg pts from unnecessary therapy & toxicities."

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

The STAMPEDE2 trial: A site survey of current patterns of care, access to imaging, and treatment of metastatic prostrate cancer in Nigeria. (ASCO 2025) - "Prostate cancer treatment modalities are available; however, access to novel agents such as abiraterone and enzalutamide was reported in 73% of centres...Clinicians expressed strong interest in participating in trials, though some gaps in infrastructure, particularly in rural areas, and limited access to advanced treatments like 177Lu-PSMA-617 were noted. The findings underscore Nigeria's potential readiness for the STAMPEDE2 trial, as well as other clinical trials and collaborative research, bolstered by an expanding radiotherapy infrastructure and clinician enthusiasm for advanced therapeutic approaches. Initiatives like the Cancer Health Fund (CHF) and the National Cancer Access Partnership (NCAP) represent significant steps towards equitable cancer care."

Metastases • Oncology • Prostate Cancer

Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician's choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer. (ASCO 2025) - P3 | "Funded by pharma& GmbH Clinical Trial Registration Number: NCT02975934 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) in men with BRCA-mutated chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) vs a control arm of physician's choice of therapy (docetaxel or androgen-receptor pathway inhibitor [ARPI] therapy: abiraterone acetate or enzalutamide) in the randomized, multicenter, open-label, phase 3 TRITON3 (NCT02975934) study. Rucaparib improves progression-free survival for patients with mCRPC with either germline or somatic BRCA mutations with a manageable safety profile. These data support the use of rucaparib as a beneficial treatment option for patients with BRCA-mutated mCRPC with germline or somatic mutations."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA

Risk of heart failure with abiraterone versus enzalutamide amongst patients diagnosed with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. (ASCO 2025) - "This meta-analysis highlights a higher HF risk with abiraterone versus enzalutamide in older mCRPC patients. Given the significant cardiovascular burden in this population, careful risk stratification and monitoring are warranted when selecting treatment. Further large-scale prospective studies are needed to confirm these findings."

Metastases • Retrospective data • Review • Cardiovascular • Castration-Resistant Prostate Cancer • Congestive Heart Failure • Genito-urinary Cancer • Heart Failure • Oncology • Prostate Cancer • Solid Tumor • AR

PSMA-PET as a way to choose oligometastatic patients for intermittent androgen deprivation: Extended follow-up of a prospective cohort of patients. (ASCO 2025) - "Distribution across NHA was: abiraterone/prednisone: 21, enzalutamide: 4, apalutamide: 4, abiraterone > enzalutamide: 1 patient. The inclusion of novel technologies on the armamentarium of prostate cancer treatment, including molecular imaging methods, radiation techniques and systemic treatments opens the opportunity to offer more effective and safer treatment modalities and also the need to re-evaluate the rule of intermittent treatment in pre-selected patients. The results of this single-center cohort ambispective analysis are promising, and longer follow-up and future prospective trials are awaited."

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

177Lu-vipivotide tetraxetan PSMA vs cabazitaxel in metastatic castration-resistant prostate cancer: A real-world analysis using the TriNetX database. (ASCO 2025) - "Patients were stratified into four groups: Group 1A (Docetaxel → Abiraterone/androgen receptor inhibitor [ARI] → 177Lu-PSMA), Group 1B (Docetaxel → Abiraterone/ARI → Cabazitaxel), Group 2A (Abiraterone/ARI → Docetaxel → 177Lu-PSMA), and Group 2B (Abiraterone/ARI → Docetaxel → Cabazitaxel). Our real-world analysis demonstrates that 177Lu-PSMA significantly improves survival and has a more favorable safety profile compared to Cabazitaxel in mCRPC. These findings support its role as a preferred third-line option. However, further large-scale studies are needed to validate these findings in broader patient populations Incidence of side effects in patients who received 177Lu-PSMA vs cabazitaxel as a third line agent for mCRPC."

Clinical • Metastases • Real-world • Real-world evidence • Anemia • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Xerostomia

Prostate adenocarcinoma to neuroendocrine tumor: A therapy-driven response? (ASCO 2025) - "There has been a rise in the incidence of NEPC, with a noted increase in neuroendocrine and AR-negative features in recent prostate cancer biopsies, particularly following the introduction of AR signaling inhibitors such as enzalutamide and abiraterone acetate. The stepwise increase in transformation rates for Groups A, B, and C suggests an association between the rate of transformation of prostate adenocarcinoma into neuroendocrine tumors and the use of modern ADT."

Castration-Resistant Prostate Cancer • Endocrine Cancer • Hormone Sensitive Prostate Cancer • Neuroendocrine Tumor • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): Survival results from a single-arm, phase II study. (ASCO 2025) - P2 | "We conducted a single arm, phase II trial of pts with mPC treated with AA+Prednisone (AAP) following the discontinuation of GnRH therapy. AAP used alone following GnRH discontinuation in pts with mPC successfully suppressed T and produced encouraging survival outcomes with an acceptable safety profile. Clinical trial information: NCT03565835"

Clinical • Metastases • P2 data • Diabetes • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Overall survival following enzalutamide resistance in metastatic castration-sensitive versus metastatic castration-resistant prostate cancer. (ASCO 2025) - "Those with prior use of other ARSIs (abiraterone, apalutamide, or darolutamide) before CRPC were excluded. After ENZA resistance (CRPC 2.0), both mCSPC and mCRPC groups showed similarly poor prognosis, with median OS under 18 months. While taxane-based chemotherapy and alternative ARSIs were commonly used as subsequent treatments, only a small proportion received radionuclide therapy or PARP inhibitors. These findings highlight the urgent need for novel approaches to improve survival in CRPC 2.0."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Exploratory biomarker analysis for progression during adaptive androgen deprivation therapy for metastatic castration sensitive prostate cancer. (ASCO 2025) - P1, P2 | "For patients with metastatic castrate sensitive prostate cancer (mCSPC), we previously reported on the feasibility of using serum total PSA and testosterone levels to decide when to stop and restart androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone analog (LHRHa) and or a new hormonal agent (NHA) like abiraterone or apalutamide (PMID: 36358643). Adaptive therapy based on serum PSA and testosterone levels is feasible for mCSPC. High PIP and high ave P/T level are significantly associated with early PSA and radiographic progression in our exploratory analyses. These biomarkers are being tested to improve adaptive therapy in our new mCSPC study (NCT06734130)."

Biomarker • Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Treatment patterns and survival by race among men with metastatic castration-resistant prostate cancer (mCRPC) in the United States: A US electronic medical record database 2020-2023. (ASCO 2025) - "Line of therapy was identified as ARPI, chemotherapy, poly (ADP-ribose) polymerase inhibitors (PARPIs), immunotherapy (pembrolizumab, sipuleucel-T), radiopharmaceuticals (Ra-223, 177Lu-PSMA-RLT), alone or in combination...Overall, ARPI (62%) [abiraterone: 25%; enzalutamide: 24%; apalutamide: 9%; darolutamide 4%] and chemotherapy (22%) [docetaxel 16%; cabazitaxel 6%] were most common first-line treatment (1L Tx) for mCRPC... ARPI and chemotherapy remained the most utilized therapies in mCRPC from 2020 to 2023 in the US. Treatment and survival outcomes did not differ significantly between Whites and AAs in mCRPC. Treatment and survival by race in mCRPC.NE, not evaluable."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR

Comparative outcomes of abiraterone and androgen receptor inhibitors (ARPIs) in metastatic castration-sensitive prostate cancer (mCSPC): A real-world analysis from the TriNetX database. (ASCO 2025) - " Using the TriNetX Research Network (2010–2024), we identified mCSPC patients treated with abiraterone (n=681), enzalutamide (n=252), or apalutamide (n=121) in combination with ADT (91–98% receiving a GnRH analog, primarily leuprolide). Outcomes included the risk of hormone resistance (ICD-10 Z19.2) and a combined endpoint of hormone resistance or docetaxel use... This real-world analysis highlights significant differences in treatment outcomes for mCSPC. Enzalutamide was associated with the highest risk of progression, while apalutamide demonstrated the most favorable outcomes, including higher sustained PSA reductions and lower progression risk. Baseline PSA differences may partially explain these findings."

Clinical • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Effect of emerin dysregulation on the very-small-nuclear phenotype and lineage plasticity associated with a clinically aggressive subtype of prostate cancer. (ASCO 2025) - "Additionally, we measured EMD expression and nuclear size in abiraterone- and enzalutamide-resistant (Abi-R/Enza-R) C4-2B cells. The presence of vsnCTCs represents a novel hallmark of an aggressive subtype of mCRPC, closely linked to EMD dysregulation and neuroendocrine differentiation. These findings highlight the potential of vsnCTCs and associated biological changes as a predictive biomarker. Our findings underscore the importance of EMD in the progression and therapeutic resistance of advanced PCa."

Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AURKA • CHGA • CTCs • MYCN • SOX2

Intensification of androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC): Patterns of use and impact on outcomes from a large academic medical center. (ASCO 2025) - "Background: ADT intensification with docetaxel and/or androgen receptor pathway inhibitors (ARPIs) has survival benefit in mHSPC...Leuprolide (85.3%), relugolix (12.1%) or degarelix (2.7%) were used for ADT. Of those who RI, 80.3% received an ARPI; 62.3% received abiraterone, 14.6% darolutamide, 13.9% apalutamide, and 9.3% enzalutamide... While PFS was longer for those who RI, these pts also had higher volume of disease, higher PSA, and higher rates of de novo disease, likely contributing to poorer OS. Even at a large academic institution, only about half of pts received intensification. Pts not given intensification were older, and patient preference was the most commonly identified reason for not receiving intensification."

Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Molecular characterization of CDK12 mutation in Chinese CRPC and its impact on first-line endocrine therapy efficacy. (ASCO 2025) - "Common regimens included Bicalutamide + Goserelin, Abiraterone + Goserelin, Flutamide + Goserelin, and Apalutamide + Goserelin. The study identifies molecular characteristics of CDK12-mutated PC associated with sensitivity or resistance to endocrine therapy. Endocrine-sensitive subtypes are characterized by ARamp, ERBB3amp, GS ≤7, and PSA ≤20 ng/mL, while endocrine-resistant subtypes include TP53, BRCA2, RB1, GS >7, and PSA >20 ng/mL. These findings emphasize the utility of NGS for improving treatment outcomes and predicting first-line endocrine therapy efficacy in CDK12-mutated PC."

Clinical • IO biomarker • Castration-Resistant Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • BRCA2 • CDK12 • ERBB3 • RB1 • TP53